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Hypo-fractionationAbstract Purpose: To assess feasibility, toxicity and biochemical relapse-free survival (b-RFS) for
a group of organ confined (OC) Saudi prostate cancer patients treated by hypo-fractionated
Volumetric Modulated Arc Radiation Therapy (VMAT) Simultaneous Integrated Boost (SIB)
Elective Nodal Irradiation (ENI) whole pelvic radiotherapy (WPRT).
Patients and methods: Between March 2009 and January 2014, 29 OC prostate cancer patients;
median age 64 years, PS 0–1 were treated in King Faisal Specialist Hospital – Riyadh, Kingdom
of Saudi Arabia using VMAT–SIB–ENI–WPRT, to a total dose of 70 Gy in 28 fractions. Twenty
Four patients (83%) were treated with neo-adjuvant; concurrent androgen deprivation therapy
(ADT). Median follow-up (FU) was 42 months (range: 18–72 months).
Results: The 3-year actuarial b-RFS for low/intermediate and high risk groups were 100%, and
48%, respectively (p= 0.09) with a median FU period of 34 months (range: 14–53 months).
Gleason Score (p= 0.02), and pretreatment PSA (p= 0.01) were predictive for biochemical failure
on univariate analysis; with no observed prostate cancer-related deaths. Grade 2 acute/late GI and
GU toxicities were 28%/0% and 17%/10% respectively with no reported grade 3/4 toxicities. FourAl Kasr
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102 M.W. Hegazy et al.(50%) out of the 8 patients with baseline partial potency, retained sexual function on long term
follow-up.
Conclusions: Hypo-fractionation dose escalation VMAT–SIB–ENI–WPRT using 2 arcs is a
feasible technique for intermediate/high risk OC prostate cancer patients, with acceptable rates
of acute/late toxicities, much favorable planning target volume (PTV) coverage, and shorter overall
treatment time. Prospective randomized controlled trials are encouraged to confirm its equivalence
to other fractionation schemes.
 2016 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Prostate cancer is the second most common solid tumor
diagnosed in men in the United States and Western Europe
[1]; a situation which is different in the middle east with
reported incidence ranging from 4.7% to 6.4% of all cancers
[2–3].
Treatment of localized prostate cancer has been proven by
clinical trials including hypofractionation radiation therapy
(RT) dose escalation with Elective Nodal Irradiation (ENI)
[4,5] and androgen deprivation therapy (ADT) combined with
RT [6,7]. Radiation therapy related toxicities is attributed to
high total RT doses, short recovery time, and the volume of
neighboring organs at risk [OARs] normal tissues (rectum
and bladder) even in prostate-only RT [4–6]. Volumetric-
modulated arc therapy (VMAT); a relatively new rotational
radiation therapy intensity modulated radiotherapy (IMRT)
technique delivering RT using continuous dynamic modula-
tion of the dose rate, field aperture, and gantry speed in the
treatment of whole pelvis (WPRT) or prostate only (±seminal
vesicles) has been reported to be equal or better for target
volume coverage and normal tissue sparing than IMRT [8].
One additional strategy to optimize the therapeutic ratio is
hypofractionation, with the advantage of the assumption that
prostate cancer is more sensitive than normal surrounding tis-
sues to fractionation (low a/b ratio) [9]. Data from 7 databases
(6000 patients) evaluating prostate cancer clinical outcomes
in relation to radiobiology confirmed the relatively low a/b
ratio for prostate cancer control (range: 0.9–2.2 Gy); a ratio
which is lower than the corresponding a/b ratios for late-
responding tissues (3–5 Gy), with hypo-fractionation
benefiting all risk groups with or without pelvic node irradia-
tion [10]. Confirmatory meta-analysis supported prostate
cancer low a/b ratio of 64 Gy [11]. Hypofractionation RT to
the prostate only is now an accepted therapeutic alternative
for high risk (HR) group of patients, with a weak evidence sup-
porting concomitant pelvic node irradiation (retrospective
phase I–II trials). Careful use of modern RT technologies with
hypofractionation is a challenge to allow treatment of smaller
volumes of critical structures (bowel, rectum, and bladder)
[12].
To our knowledge; this study is the first experience in the
Middle East Region using hypofractionated VMAT–SIB–E
NI–WPRT technique with daily Image guided radiotherapy
(IGRT) for a group of OC prostate cancer Saudi patients
to assess its feasibility, toxicity and long-term b-RFS and
to compare these outcomes with internationally published
data.Patients and methods
Between March 2009 and January 2014, 29 newly diagnosed,
non-metastatic, biopsy-proven adenocarcinoma localized
prostate cancer patients with no prior therapy; referred to
radiation Oncology service – King Faisal Specialist Hospital
(KFSH) – Riyadh, Kingdom of Saudi Arabia-KSA were
treated with definitive Volumetric Modulated–Simultaneous
Integrated Boost–Elective Nodal Irradiation–Whole Pelvis
Radiotherapy (VMAT–SIB–ENI–WPRT) to a total dose of
70 Gy in 28 fractions (250 cGy/Fx). Patients with distant
metastases or recurrent disease and those who did not
complete their treatment, in addition to those treated with
palliative intent were excluded from the study.
All Patients underwent pre-treatment trans-rectal ultra-
sound prostate biopsy; median number of cores collected
was 9 [6–12]. Pre-treatment work-up included: MRI pelvis to
evaluate extraprostatic extension, pelvic lymph node metas-
tases and prostate volumetric assessment, CT scan of the
chest–abdomen and pelvis and nuclear medicine (NM) bone
scan. Patients were stratified to risk groups based upon current
NCCN prognostic risk groupings (www.nccn.org). Baseline
demographics and clinical characteristics of the treated group
are shown in Table 1. Due to the small numbers of low risk
(5 patients) and intermediate risk patients (4 patients), both
groups were merged together as one group for statistical
analysis.
Among the 29 patients; 24 (83%) were treated by androgen
deprivation therapy (ADT): a total of 6-months for
intermediate-risk patients (14%) and 2–4 months prior to
VMAT–SIB–WPRT. While for high-risk patients (69%)
ADT was continued to a total duration of P24–36 months.
Biochemical failure was defined as per the Phoenix-
Radiation Therapy Oncology Group (RTOG) criteria: nadir
prostate-specific antigen (PSA) post radiotherapy concentra-
tion plus 2 ng/mL [13].
Written informed consent was obtained from all patients
Patients were clinically assessed during treatment on a weekly
basis. Acute (during RT) and late (P90 days post treatment)
GU and GI toxicities were documented based on Radiation
Therapy Oncology Group (RTOG) Criteria for Adverse
Events (www.RTOG.org). The maximum toxicity suffered
was recorded.
Post treatment follow-up visits were performed by the treat-
ing radiation oncologist every 3 months for the first 2 years,
followed by every 4–6 months for the next 3 years and yearly
Table 1 Baseline demographic and clinical characteristics of
the whole group.
Characteristic Number (N= 29) %
Median age (range)
64 years (50–81)
665 years 14 48
>65 years 12 53
Tumor stage
T1 10 34.5
T2/T3* 19 65.5
Gleason score
2–6 10 34.5
7 9 31
8–10 10 34.5
PSA
610 ng/mL 5 17
>10–620 ng/mL 7 24
>20–650 ng/mL 6 20
>50–6100 ng/dl 6 20
>100–6200 ng/dl 5 17
Risk group
Low risk (LR) 5 17
Intermediate risk (IR) 4 14
High risk (HR) 20 69
ADT use
Yes 24 82.8
Duration 66 months 3 10.4
Duration >6 months 21 72.4
% of core involvement
Median (range) 60 (20–100)
Baseline** sexual function
Full potency – –
Partial potency 8 27.5
Impotent 21 72.5
* One pt was T3.
** Pre-RT, ADT, androgen deprivation therapy; PSA, prostate-
specific antigen.
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2–3 months. Toxicity occurring 90 days after the end of RT
was classified as late toxicity.
Erectile function was assessed using a three-tier grading sys-
tem at baseline (before RT) and after completion of Androgen
Deprivation therapy (ADT) and at regular follow-up visits:
 Full potency: ability to have full erections adequate for
penetration;
 Partial potency: ability to achieve penetration but either
aids are needed or the patient reports difficulty in doing
so; or
 Impotent: inability to achieve an erection adequate for
penetration.
Simulation, contouring, and planning
Computed tomography (CT) was acquired in the supine posi-
tion, with 2-mm thick slices from the upper abdomen to 5 cmbelow the ischial tuberosities after immobilization with Knee
and feet support immobilization devices. Patients were
instructed to have a comfortably full bladder and an empty
rectum at CT acquisition and before each treatment.
Planning and dose parameters
All patients were treated using two arcs VMAT plan with
6–10 MV photons. The entire cohort was treated to a total
dose of 70 Gy in 28 daily fractions (250 cGy/fraction) over
51/2–6 weeks.
The clinical target volume (CTV); CTV-70 was defined as
the entire prostate and seminal vesicle (if involved); CTV-56
included the whole prostate and seminal vesicle (if not
involved). CTV-50.4 included pelvic Lymph nodes (in high risk
patients) or a 0.7-cm anisotropic expansion volume of the
obturator, common, external and internal iliac vessels, with
trimming from adjacent bone, muscle, bowel and bladder.
The nodal CTV contouring started at the level of L5-S1;
external iliac and obturator nodal volumes were drawn till
the top of femoral head and symphysis pubis respectively.
Pelvic lymph node volumes were drawn following the RTOG
consensus recommendations.
The planning target volume (PTV)
PTV-70 was generated by adding anisotropic 0.5 cm margin to
the CTV-70 apart from posteriorly where 0.3 cm margin was
added (to decrease prostate-rectal interface dose) (Figs. 1
and 2). PTV-56 was a 0.7 cm anisotropic expansion from
CTV56 except posteriorly (0.5–0.7 cm) depending on rectal
fullness (Fig. 3). While for PTV-50.4; a margin of 0.3–0.5 cm
was added to CTV 50.4 and 0.8–1.5 cm added volume anterior
to S1–S3 (presacral nodes) (Fig. 4).
Contouring of the Organs at risk (OAR) followed the
RTOG pelvic normal tissue contouring guidelines. The rectum
was outlined from the level of the ischial tuberosities to the rec-
tosigmoid flexure. The whole bladder was contoured; femoral
heads were delineated to the level of the ischial tuberosities.
The bowel was contoured as the entire volume of peritoneal
space to within 1 cm of the cranial margin of the nodal PTV.
Dose constraints used for the small bowel, rectum, bladder
and PTV are shown in Table 2.
Online image-guided radiotherapy (IGRT)
Gold fiducial markers were implanted by the interventional
radiologist under U/S guidance prior to radiotherapy for
tracking purposes on daily imaging for verification and online
correction. On Board imaging (OBI) Daily image guidance
with Cone Beam CT (CBCT) was performed for all patients.
Statistical analysis
The collected data was analyzed using Kaplan–Meier method
for biochemical relapse-free survivals (b-RFS) and compar-
isons were made using the log-rank test. Clinical characteristics
were compared using the chi-square test or Fisher exact test for
categorical variables. Statistical analysis was performed using
SPSS ver. 20.0.0 software (SPSS Inc., Chicago, IL, USA).
Figure 1 PTV70 (prostate only).
Figure 2 PTV70 (prostate + seminal vesicle if SV involved).
Figure 3 PTV56 (prostate + seminal vesicle).
Figure 4 PTV50.4 (HR patients, lymph nodes included).
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Table 2 Dose constraints of the studied LR/IM and HR
prostate cancer patients.
PTV P95% volume to receive 100%
of prescribed dose
LR/IR
Bladder V60 < 25%
Rectum V70 < 15%
Small bowel bag mean dose < 35 Gy
HR
Bladder V50 < 50%
Rectum <10 cc volume to receive dose > 70 Gy
Small bowel bag mean dose < 35 Gy
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The study included 29 patients; median age 64 years
(50–81 years). T1–2 disease constituted 96.5%, initial
PSA > 10 ng/ml was reported in 76%, GS 6 7 was patholog-
ically documented in 65% of the group. No ADT was reported
for 5 patients (17%), those of the low risk (LR) group.
Median time to post-treatment PSA nadir was 14 months
(range: 7–32 months) with a mean/median of 3.2/0.5 ng/dl
compared to pre-RT mean/median initial PSA of 50.5/38 ng/dl
respectively (Table 1).
Erectile function and potency
Of the 29 patients, 8 had baseline (prior to RT) partial potency
(27.5%) and the rest [21] were impotent (72.5%). Four out of
the 8 patients (50%) retained functional potency on long-term
follow-up (median 16 months; range: 14–32 months); all were
among the low and Intermediate risk patients (Table 1).
Survival parameters
The 3 and 4 year actuarial overall survival for the whole group
was 88% and 72% at a median FU of 42 months (range:
16–67 months) while the 2 and 3 years b-RFS for the whole
group was 90% and 72% at a median FU of 34 months (range:
14–53 months). For age category of <65 vs. P65 years; the 4
actuarial overall survival was 71% and 74% and the actuarial
3 year b-RFS survival was 70% and 73% respectively.
Biochemical failure rates
The actuarial 3 year b-RFS for the whole group was 70%, with
a median FU period of 34 months (range: 14–53 months).
Only 4 patients of the high risk (HR) group with initial
PSA > 100 ng/dl, developed biochemical failure at 9, 22, 25
and 26 months respectively; all of them developed bone metas-
tases at 12, 27, 30 and 26 months, respectively. The calculated
actuarial 3 year b-RFS rates for LR/IR and HR groups; based
on the PSA-nadir plus 2 ng/mL; was 100%, and 48%, respec-
tively (p= 0.09) Fig. 5 (a and b). Pretreatment PSA level
(p= 0.01) and Gleason score (p= 0.03) were the only two sig-
nificant factors for biochemical failure by univariate analysis
(Fig. 5c and d). Percentage of positive biopsy cores
(p= 0.07), and T-stage (p= 0.09) is shown in (Table 3). Noprostate cancer-related deaths were observed in the group
during the follow up period.
Treatment compliance
All patients tolerated the treatment well with no planned or
unplanned treatment breaks. Radiotherapy treatment course
was started after the 2nd month of Neo-adjuvant ADT and
started with the 3rd ADT course. Overall treatment time was
respected, no treatment breaks were encountered and all
patients ended their RT course within the planned treatment
duration (51/2–6 weeks [range: 39–44 days]).
GI toxicity
Acute GI toxicity scores were: grade 1 in 69% and grade 2 in
28% of patients. Late toxicity scores were: grade 0 in 80% and
grade 1 in 20% of patients. There was no grade 3 or 4 acute or
late GI toxicity with a median follow up of 42 months
(Table 4).
GU toxicity
Acute GU toxicity scores were: grade 1 in 83% and grade 2 in
17% of patients. Late GU toxicity scores were: grade 0 in 50%,
grade 1 in 40% and grade 2 in 10% of patients. There was no
grade 3 or 4 acute or late GU toxicity with a median follow up
period of 42 months (Table 4).
Discussion
This study highlights the first National (Kingdom of Saudi
Arabia) experience in the Middle East Region using
VMAT–SIB–ENI in the treatment of a selected group of 29
Prostate cancer patients treated with the hypofractionated
schedule of 70 Gy delivered at 2.5 Gy/fraction using
VMAT–SIB technique with pelvic lymph node treatment.
The treatment results were encouraging and at least compara-
ble to what has been achieved with other therapeutic
approaches (IMRT–Brachytherapy) delivering high radiation
doses in the treatment of prostate cancer in western patient’s
population series [14–16].
In the current study, Age, risk and percentage of hormone
treatment (HT) among the studied subjects were comparable
to others Table 1 [10,14–16]. Erectile/sexual function is usually
affected in 75% of the patients on long term ADT [17], about
1 in 5 men (20%) keep the ability to maintain an erection. In
addition to obesity, comorbidities (Diabetes, CVDs) and pre-
treatment sexual aid usage – all of which- increases patients’
risk of radiation induced ED. In the current study only 8
patients (28%) reported baseline partial potency and 50% of
them reported to be sexually active on long term follow up;
a finding which is in agreement with the reported 43.6% base-
line Sexual dysfunction (a score >2 on the LENT/SOM scale)
with a further score deterioration of 83.5% during neo-
adjuvant hormone therapy and before radiotherapy; 26% of
patients can expect to retain sexual function at 5 years after
radiotherapy treatment. Partial recovery was reported after
intermittent and continuous ADT in 16–28% and 10% respec-
tively at a FU period of 15–24 months [17,18].
Figure 5 (a and b) Kaplan Meier estimates for PSA-bRFS for whole and LR/IR vs. HR groups treated by Hypo-Fx VMAT. (c) Kaplan
Meier estimates for 29 patients. PSA-bRFS treated by Hypo-Fx VMAT (GS 6 7 vs. GS > 7). (d) KM estimates for PSA-bRFS treated by
Hypo-Fx VMAT (PSA 6 20 vs. PSA > 20).
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(PSA nadir plus 2 ng/mL) were 100%, and 47%, for low/
intermediate and high risk patients respectively at a median
follow up period of 34 months (range: 14–53 months). Results
which are lower than a recently published Korean report using
Hypo-fractionated IMRT for 30 patients. at a median FU per-
iod of 74.4 months (18.8–125.9) with 5-year actuarial b-RFS
rates of 100%, and 88.5%, for low/intermediate, and high-
risk patients respectively; in addition to that reported at the
Cleveland Clinic Foundation for 770 patients. treated with the
same hypo-fractionated IMRT schedule with a median FU
of 66 months (8–86 months) with reported 5-year b-RFS of
94%, 83%, and 72%, for the low, intermediate and high risk
patients’ cohort respectively [19,20]. An explanation of which
is that our cohort was recently treated after the introductionof the VMAT technology to the hospital in 2009 and hence
longer follow up months are needed, in addition to the high
initial PSA > 100 ng/dl for all of the 4 relapsed patients.
High-risk group with high risk of metastases and Prostate
Cancer Specific Mortality (PCSM) are those patients with a
biopsy GS 8–10, high PSA> 20–50 ng/dl and clinical stage
cT3b–T4. Conversely, patients at low risk of metastases and
PCSM are those with biopsy GS < 7, clinical stage <cT3a
and time to biochemical progression > 3 years [21,22]. Similar
finding in this study was reported with a better b-RFS for
those patients with GS 6 7 and PSA < 20 ng/dl compared to
those with a higher score (Table 3).
Elective Pelvic node in addition to prostate irradiation
aiming at dose escalation using IMRT might lead to a better
treatment outcome in HR prostate cancer patients, with
Fig. 5 (continued)
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grade P2 bowel toxicity was 40% and 50% for 50 and
55 Gy respectively, suggesting both volume and dose relation-
ships for acute effects. While, late RTOG diarrhea grade P2
was reported with a larger bowel volume (BV) irradiated
(BV40 > 124 cm3 (p= 0.04), BV45 > 71 cm3 (p= 0.03) and
BV60 > 2 cm3 (p= 0.01) [23].
Acute and late GI/GU toxicities of the current study
compared to other series (Tables 4 and 5); showed a slightly
higher acute GI grade P2 toxicity compared to other studies
[18,24–27] albeit a lower % of late GI grade P2 toxicity and
comparable acute/late GU toxicities, a finding which might
be explained by the larger BV irradiated during pelvic ENI.
Hypo-fractionated VMAT radiotherapy was not inferior
to standard fractionated radiotherapy in terms of acutegenitourinary and gastrointestinal toxicity for patients with
intermediate and high-risk prostate cancer.
Two important issues addressing prostate cancer RT need
to be discussed:
First issue: Hypo-fractionation and its equivalence to stan-
dard fractionation schedules; According to the presumed
a/b ratio for prostate cancer using the linear quadratic
model, the BED of 70 Gy delivered at 2.5 Gy/fraction
would be about 85 Gy (a/b: 1.5) and about 74 Gy (a/b:10)
if delivered at 1.8 Gy/fraction [28].
Accurate a/b ratio is still controversial; a meta-analysis of
25 studies with > 14,000 patients concluded an a/b ratio
of approximately 1.5 Gy due to its slow growth. Based on
this assumption, hypofractionated radiotherapy (HFRT)
Table 3 Potential prognostic factors for PSA biochemical
relapse-free survival (b-RFS).
Factors No. of patients. PSA-relapse free survival %
1 years 2 years 3 years p value
All 29 97 90 70 NA
Age (median 64 years)
<65 15 100 87 70 0.325
P65 14 100 92 73
T-stage
T1 10 100 100 100 0.09
T2–T3 19 94 84 47
Gleason score
67 19 100 100 100
>7 10 90 75 43 0.02
PSA
<20 12 100 100 100 0.01
P20 17 92 81 61
Risk group
LR/IR 9 100 100 100 0.09
HR 20 100 85 48
LR, low risk; IR, intermediate risk; HR, high risk.
Table 4 GI/GU toxicity results in relation to the study risk
groups.
Acute grade 2 toxicity Late grade 2 toxicity
GI GU GI GU
No. (%) No. (%) No. (%) No. (%)
LR/IR 3 (11%) 2 (6.7%) 0% 1 (3.4%)
HR 5 (17%) 3 (10%) 0% 2 (6.8%)
p-value 0.45 0.28 – 0.24
LR: low risk, IR: intermediate risk, HR: high risk.
Table 5 GI/GU study toxicity results compared to other series.
Trial Dose#Fx AcutePG2 toxicit
GI
No. (%)
CHHiP24 74 Gy#37 3 (2.3%)
60 Gy#20 3 (2.3%)
57 Gy#19 1 (0.8%)
HYPRO25 78 Gy#39 42 (13%)
64.6 Gy#19 43 (13%)
ISHII26 VMAT
78 Gy#39 18 (18%)
Kupelian20 70 Gy#28 23 (23%)
Lips27 76 Gy#35 98 (30%)
Current study* 70 Gy#28 8 (28%)
* No grade 3/4 toxicity was recorded.
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with fraction sizes of 1.8–2 Gy, in addition to being more
convenient for the patient with lower costs for the health
care system [29].
Table 6 summarizes the ongoing phase-III randomized
controlled trials (RCTs) for low/intermediate risk prostate
cancer patients trying to answer whether HFRT is equiva-
lent to conventionally fractionated radiotherapy (CFRT)
in terms of b-RFS and toxicity. RTOG 0415- phase III
(RCT) and a phase I/II trial by Kupelian et al. [18] demon-
strated an equivalence between both fractionation regi-
mens. If the a/b= 10 but with an a/b= 1.5, HFRT
should produce better rates of biochemical control because
being less than the reported a/b= 3 Gy for late reactions of
neighboring OARs (including rectum). An assumption
which was proved by the CHHip [22] trial showing that
HFRT was equally well tolerated compared to CFRT treat-
ment at 2 years with suggested a/b values as low as 1.5 Gy.
The second issue: Radiation delivery technique and
toxicities
Radiation therapy GI and GU toxicities reported from pre-
vious hypo-fractionation schedules were due to the use of
conventional non-conformal RT techniques but with
modern conformal tailored, sophisticated treatment plans
with improved targeting and treatment delivery techniques
(e.g.: IMRT–VMAT) with the implementation of image
guidance using daily cone beam CT (CBCT) a better
tolerated treatment outcome with possible improvement
in the PSA control is expected [30].
Intra-fraction motion (real-time motion of the prostate dur-
ing treatment delivery) is only lately being characterized.
Until the target (i.e., the prostate) position is accurately
hit every day during actual radiation delivery, the benefits
of hypofractionation with EBRT will be questioned.
Although localization and motion problems are important,
independent of any fractionation schedule, the margin of
error for a smaller number of fractions could be smaller
compared with a larger number of fractions. This isy LatePG2 toxicity
GU GI GU
No. (%) No. (%) No. (%)
9 (7%) 6 (4.3%) 3 (2.2%)
10 (7.6%) 5 (3.6%) 3 (2.2%)
9 (7%) 2 (1.4%) 0%
73 (22%) – –
75 (23%) – –
– –
13 (13%)
19 (19%) 10 (10%) 13 (12%)
160 (47%) 72 (22%) 42 (13%)
5 (17%) 0% 3 (10%)
Table 6 Ongoing phase III studies comparing conventional and hypo-fractionated-RT.
Trial Identifier Status Estimated No. Total dose (Gy) Risk
RTOG 0415 NCT00331773 Unknown 1067 70#28 Low
UK MRC/CHHiP NCT00392535 Accruing 3216 74#37 Low
57#19 & 60#20 Intermediate
NCIC NCT00304759 Ongoing 1204 78#39 & 60#20 Intermediate
MD Anderson NCT00667888 Ongoing 225 78#39 &60#20 Low Intermediate
Hypofractionated Volumetric Modulated Arc Radiotherapy in prostrate cancer 109currently untested and should be the subject of future inves-
tigations.
Conclusion
This is the first published report in the Middle East evaluating
feasibility, treatment related toxicities of high dose hypo-
fractionation VMAT–SIB–ENI–RT for HR prostate cancer
patients with acceptable PSA b-RFS. Acute and late GU
and GI toxicities are comparable to international reports.
Hypo-fractionated VMAT–SIB–ENI is safe and a feasible
dose escalation method; a novel technique in RT treatment
delivery that needs further assessment in prospective random-
ized controlled trials.
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